Although the study has been extended, October was the date for the primary data to be compiled, so I interpret that as to mean that we still have results reported by the end of Qtr. 1. Perhaps they felt the need to extend the trial to provide further support for the NDA as the results were not as robust as hoped for. Anyone care to comment?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.